Synaptic Density in Multiple Sclerosis

dc.contributor.authorLuoma, Amelie
dc.contributor.authorMatilainen, Markus
dc.contributor.authorTuisku, Jouni Mikael
dc.contributor.authorAarnio, Richard
dc.contributor.authorNikkilä, Taru
dc.contributor.authorLaaksonen, Sini
dc.contributor.authorKoivumäki, Mikko
dc.contributor.authorHonkonen, Eveliina
dc.contributor.authorNylund, Marjo
dc.contributor.authorWahlroos, Saara
dc.contributor.authorSolin, Olof
dc.contributor.authorChen, Ming-Kai
dc.contributor.authorToyonaga, Takuya
dc.contributor.authorLehto, Jussi
dc.contributor.authorSnellman, Anniina
dc.contributor.authorRinne, Juha O.
dc.contributor.authorAiras, Laura M.
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=kliiniset neurotieteet|en=Clinical Neurosciences|
dc.contributor.organizationfi=kuvantaminen ja kliininen diagnostiikka|en=Imaging and Clinical Diagnostics|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.69079168212
dc.contributor.organization-code1.2.246.10.2458963.20.74845969893
dc.converis.publication-id499408935
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/499408935
dc.date.accessioned2026-01-21T12:19:38Z
dc.date.available2026-01-21T12:19:38Z
dc.description.abstract<p><strong>Background and Objectives</strong><br></p><p>Multiple sclerosis (MS) is a chronic inflammatory disease coupled with neurodegenerative processes affecting both the white matter and gray matter (GM) in the CNS. Several histopathologic studies have reported a reduction in synaptic density in various areas of the brain. However, this pathologic feature is yet an unexplored entity among people with MS (pwMS). Therefore, we sought to investigate synaptic loss in vivo by quantifying the synaptic vesicle glycoprotein 2A using [<sup>11</sup>C]UCB-J-PET imaging and to explore associations with clinical and cognitive measures.<br></p><p><strong>Methods</strong><br></p><p>Ten pwMS and 8 healthy controls (HCs) underwent high-resolution [<sup>11</sup>C]UCB-J-PET imaging and MRI. SV2A availability was determined using the tissue-to-plasma concentration ratio at equilibrium (distribution volume; VT). We furthermore explored associations between PET imaging results and clinical and cognitive measures in pwMS (assessed with the Expanded Disability Status Scale (EDSS) and Symbol Digit Modalities Test [SDMT]). In addition, we considered volumetric, clinical, and cognitive measures during a 5-year period before PET imaging.<br></p><p><strong>Results</strong><br></p><p>Ten pwMS (7 women [70%], median [interquartile range] age, 53 [50-56]) years were compared with 8 HCs (6 women [75%]; age, 51 [50-70] years). PwMS had a significantly lower SV2A availability in the cortical GM (pwMS: mean [SD], V<sub>T</sub> = 15.65 mL/cm3 [2.26]; HCs: V<sub>T</sub> = 18.14 mL/cm<sup>3</sup> [2.09]; p = 0.029, t test), as well as in several subcortical regions. Moreover, a lower SV2A availability in cortical GM correlated significantly with reduced SDMT values in pwMS (r = 0.071, p = 0.021; Spearman correlation coefficient). No association between physical disability (measured using EDSS) and SV2A availability was found.<br></p><p><strong>Discussion</strong><br></p><p>Using in vivo [<sup>11</sup>C]UCB-J PET imaging, we provide evidence of reduced synaptic density in pwMS. Furthermore, the results reveal a link between synaptic loss and cognitive impairment. These findings highlight the potential of [<sup>11</sup>C]UCB-J PET imaging as a promising tool for assessing clinically relevant aspects of GM pathology in MS.<br></p>
dc.identifier.eissn2332-7812
dc.identifier.jour-issn2332-7812
dc.identifier.olddbid212344
dc.identifier.oldhandle10024/195362
dc.identifier.urihttps://www.utupub.fi/handle/11111/50615
dc.identifier.urlhttps://doi.org/10.1212/nxi.0000000000200435
dc.identifier.urnURN:NBN:fi-fe2025082786343
dc.language.isoen
dc.okm.affiliatedauthorLuoma, Amelie
dc.okm.affiliatedauthorMatilainen, Markus
dc.okm.affiliatedauthorTuisku, Jouni
dc.okm.affiliatedauthorAarnio, Richard
dc.okm.affiliatedauthorNikkilä, Taru
dc.okm.affiliatedauthorLaaksonen, Sini
dc.okm.affiliatedauthorKoivumäki, Mikko
dc.okm.affiliatedauthorHonkonen, Eveliina
dc.okm.affiliatedauthorNylund, Marjo
dc.okm.affiliatedauthorWahlroos, Saara
dc.okm.affiliatedauthorSolin, Olof
dc.okm.affiliatedauthorLehto, Jussi
dc.okm.affiliatedauthorSnellman, Anniina
dc.okm.affiliatedauthorRinne, Juha
dc.okm.affiliatedauthorAiras, Laura
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3112 Neurosciencesen_GB
dc.okm.discipline3112 Neurotieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.publisher.placePHILADELPHIA
dc.relation.articlenumbere200435
dc.relation.doi10.1212/NXI.0000000000200435
dc.relation.ispartofjournalNeurology, Neuroimmunology and Neuroinflammation
dc.relation.issue5
dc.relation.volume12
dc.source.identifierhttps://www.utupub.fi/handle/10024/195362
dc.titleSynaptic Density in Multiple Sclerosis
dc.year.issued2025

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
luoma-et-al-2025-synaptic-density-in-multiple-sclerosis.pdf
Size:
557.16 KB
Format:
Adobe Portable Document Format